Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05270733 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv8
  2. Primary and study completion dates: Dec 31, 2024 to Dec 31, 2026v7
  3. Re-verified, no change to tracked fieldsv6
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Dec 1, 2022 to Nov 10, 2022
    • Site details revised
    v5
  5. Start date: Sep 1, 2022 to Dec 1, 2022v4
Show 2 earlier versionsHide 2 earlier versions
  1. Start date: Jun 1, 2022 to Sep 1, 2022v3
  2. Primary completion date: Dec 31, 2023 to Dec 31, 2024
    • Start date: Mar 1, 2022 to Jun 1, 2022
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The investigators propose to improve the possibility of reaching skin resolution by identifying certain markers or gene patterns that may predict patient response to certain psoriasis drugs ahead of time, thus eliminating or reducing the trial-and-error approach often employed. The ability to rule out (or in) specific therapeutics based on predictive efficacy would lead to a more personalized approach for psoriasis treatment. To do this, the investigators will be asking participants to try two different already on the market FDA-approved psoriasis drugs for 8 weeks at a time. The investigators will be monitoring participants skin for improvements as well as taking blood and skin samples at least three times. Investigators may also ask to take stool samples and/or skin swabs.
Trial Details
NCT Number NCT05270733
Lead Sponsor University Hospitals Cleveland Medical Center
Collaborators: LEO Foundation, Case Western Reserve University
Conditions
(from sponsor)		 Psoriasis
Related terms Psoriasis
Enrollment 56 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov